Cargando…
Analysis of cytotoxic T lymphocytes from a patient with hepatocellular carcinoma who showed a clinical response to vaccination with a glypican-3-derived peptide
Glypican-3 (GPC3), which is a carcinoembryonic antigen, is overexpressed in human hepatocellular carcinoma (HCC). Previously, we performed a phase I clinical trial of GPC3-derived peptide vaccination in patients with advanced HCC, and reported that GPC3 peptide vaccination is safe and has clinical e...
Autores principales: | , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
D.A. Spandidos
201
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3829797/ https://www.ncbi.nlm.nih.gov/pubmed/23903757 http://dx.doi.org/ 10.3892/ijo.2013.2044 |
_version_ | 1782291390856691712 |
---|---|
author | TADA, YOSHITAKA YOSHIKAWA, TOSHIAKI SHIMOMURA, MANAMI SAWADA, YU SAKAI, MAYUKO SHIRAKAWA, HIROFUMI NOBUOKA, DAISUKE NAKATSURA, TETSUYA |
author_facet | TADA, YOSHITAKA YOSHIKAWA, TOSHIAKI SHIMOMURA, MANAMI SAWADA, YU SAKAI, MAYUKO SHIRAKAWA, HIROFUMI NOBUOKA, DAISUKE NAKATSURA, TETSUYA |
author_sort | TADA, YOSHITAKA |
collection | PubMed |
description | Glypican-3 (GPC3), which is a carcinoembryonic antigen, is overexpressed in human hepatocellular carcinoma (HCC). Previously, we performed a phase I clinical trial of GPC3-derived peptide vaccination in patients with advanced HCC, and reported that GPC3 peptide vaccination is safe and has clinical efficacy. Moreover, we proposed that a peptide-specific CTL response is a predictive marker of overall survival in patients with HCC who receive peptide vaccination. In this study, we established GPC3-derived peptide-specific CTL clones from the PBMCs of an HLA-A ( * ) 02:07-positive patient with HCC who was vaccinated with an HLA-A2-restricted GPC3 peptide vaccine and showed a clinical response in the phase I clinical trial. Established CTL clones were analyzed using the IFN-γ ELISPOT assay and a cytotoxicity assay. GPC3 peptide-specific CTL clones were established successfully from the PBMCs of the patient. One CTL clone showed cytotoxicity against cancer cell lines that expressed endogenously the GPC3 peptide. The results suggest that CTLs have high avidity, and that natural antigen-specific killing activity against tumor cells can be induced in a patient with HCC who shows a clinical response to vaccination with the GPC3 ( 144–152 ) peptide. |
format | Online Article Text |
id | pubmed-3829797 |
institution | National Center for Biotechnology Information |
language | English |
publishDate |
201 |
publisher |
D.A. Spandidos
|
record_format | MEDLINE/PubMed |
spelling | pubmed-38297972013-11-18 Analysis of cytotoxic T lymphocytes from a patient with hepatocellular carcinoma who showed a clinical response to vaccination with a glypican-3-derived peptide TADA, YOSHITAKA YOSHIKAWA, TOSHIAKI SHIMOMURA, MANAMI SAWADA, YU SAKAI, MAYUKO SHIRAKAWA, HIROFUMI NOBUOKA, DAISUKE NAKATSURA, TETSUYA Int J Oncol Articles Glypican-3 (GPC3), which is a carcinoembryonic antigen, is overexpressed in human hepatocellular carcinoma (HCC). Previously, we performed a phase I clinical trial of GPC3-derived peptide vaccination in patients with advanced HCC, and reported that GPC3 peptide vaccination is safe and has clinical efficacy. Moreover, we proposed that a peptide-specific CTL response is a predictive marker of overall survival in patients with HCC who receive peptide vaccination. In this study, we established GPC3-derived peptide-specific CTL clones from the PBMCs of an HLA-A ( * ) 02:07-positive patient with HCC who was vaccinated with an HLA-A2-restricted GPC3 peptide vaccine and showed a clinical response in the phase I clinical trial. Established CTL clones were analyzed using the IFN-γ ELISPOT assay and a cytotoxicity assay. GPC3 peptide-specific CTL clones were established successfully from the PBMCs of the patient. One CTL clone showed cytotoxicity against cancer cell lines that expressed endogenously the GPC3 peptide. The results suggest that CTLs have high avidity, and that natural antigen-specific killing activity against tumor cells can be induced in a patient with HCC who shows a clinical response to vaccination with the GPC3 ( 144–152 ) peptide. D.A. Spandidos 2013 -07- 31 /pmc/articles/PMC3829797/ /pubmed/23903757 http://dx.doi.org/ 10.3892/ijo.2013.2044 Text en Copyright © 2013, Spandidos Publications http://creativecommons.org/licenses/by/3.0 This is an open-access article licensed under a Creative Commons Attribution-NonCommercial 3.0 Unported License. The article may be redistributed, reproduced, and reused for non-commercial purposes, provided the original source is properly cited. |
spellingShingle | Articles TADA, YOSHITAKA YOSHIKAWA, TOSHIAKI SHIMOMURA, MANAMI SAWADA, YU SAKAI, MAYUKO SHIRAKAWA, HIROFUMI NOBUOKA, DAISUKE NAKATSURA, TETSUYA Analysis of cytotoxic T lymphocytes from a patient with hepatocellular carcinoma who showed a clinical response to vaccination with a glypican-3-derived peptide |
title |
Analysis of cytotoxic T lymphocytes from a patient with hepatocellular carcinoma who showed a clinical response to vaccination with a glypican-3-derived peptide
|
title_full |
Analysis of cytotoxic T lymphocytes from a patient with hepatocellular carcinoma who showed a clinical response to vaccination with a glypican-3-derived peptide
|
title_fullStr |
Analysis of cytotoxic T lymphocytes from a patient with hepatocellular carcinoma who showed a clinical response to vaccination with a glypican-3-derived peptide
|
title_full_unstemmed |
Analysis of cytotoxic T lymphocytes from a patient with hepatocellular carcinoma who showed a clinical response to vaccination with a glypican-3-derived peptide
|
title_short |
Analysis of cytotoxic T lymphocytes from a patient with hepatocellular carcinoma who showed a clinical response to vaccination with a glypican-3-derived peptide
|
title_sort | analysis of cytotoxic t lymphocytes from a patient with hepatocellular carcinoma who showed a clinical response to vaccination with a glypican-3-derived peptide |
topic | Articles |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3829797/ https://www.ncbi.nlm.nih.gov/pubmed/23903757 http://dx.doi.org/ 10.3892/ijo.2013.2044 |
work_keys_str_mv | AT tadayoshitaka analysisofcytotoxictlymphocytesfromapatientwithhepatocellularcarcinomawhoshowedaclinicalresponsetovaccinationwithaglypican3derivedpeptide AT yoshikawatoshiaki analysisofcytotoxictlymphocytesfromapatientwithhepatocellularcarcinomawhoshowedaclinicalresponsetovaccinationwithaglypican3derivedpeptide AT shimomuramanami analysisofcytotoxictlymphocytesfromapatientwithhepatocellularcarcinomawhoshowedaclinicalresponsetovaccinationwithaglypican3derivedpeptide AT sawadayu analysisofcytotoxictlymphocytesfromapatientwithhepatocellularcarcinomawhoshowedaclinicalresponsetovaccinationwithaglypican3derivedpeptide AT sakaimayuko analysisofcytotoxictlymphocytesfromapatientwithhepatocellularcarcinomawhoshowedaclinicalresponsetovaccinationwithaglypican3derivedpeptide AT shirakawahirofumi analysisofcytotoxictlymphocytesfromapatientwithhepatocellularcarcinomawhoshowedaclinicalresponsetovaccinationwithaglypican3derivedpeptide AT nobuokadaisuke analysisofcytotoxictlymphocytesfromapatientwithhepatocellularcarcinomawhoshowedaclinicalresponsetovaccinationwithaglypican3derivedpeptide AT nakatsuratetsuya analysisofcytotoxictlymphocytesfromapatientwithhepatocellularcarcinomawhoshowedaclinicalresponsetovaccinationwithaglypican3derivedpeptide |